Elizabeth (Betsy) Munnell’s Post

View profile for Elizabeth (Betsy) Munnell, graphic

Business and Career Development Coach for Lawyers | Former Harvard Law School Advisor | 25-Year BigLaw Partner

When (1) your company is a stand-in for the Danish economy, (2) you've dethroned LVMH (Louis Vuitton, Moët Hennessy, and countless "Maisons" if you must know) as the biggest company in Europe, (3) your '23 operating profit has grown 40-46%, (4) the global market for obesity and anti-diabetes drugs is beyond exploding, and (5) Wegovy and Ozempic appear to be only the beginning of a wave of promising applications for semaglutide... well, then you can do whatever you want, including threaten the EU to decamp pretty much altogether in response to new rules reducing guaranteed exclusivity. #bigpharma

Europe’s most valuable drugmaker Novo Nordisk is threatening the EU with a shift to the U.S.

Europe’s most valuable drugmaker Novo Nordisk is threatening the EU with a shift to the U.S.

finance.yahoo.com

To view or add a comment, sign in

Explore topics